[1] Treede R D,Rief W, Barke A,et al. A classification of chronic pain for ICD-11[J]. Pain, 2015, 156(6):1003-1007. [2] 王雅杰, 王宁. 重视吗啡治疗癌痛病人的个体差异[J]. 药学服务与研究, 2010, 10(2):81-84. [3] Hirota T, Ieiri I, Takane H, et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy[J]. Drug Metab Dispos, 2003, 31(5): 677-680. [4] Handal M, Grung M, Skurtveit S, et al. Pharmacokinetic diffrences of morphine and morphine-glucuronides are reflected in locomotor activity[J]. Pharmacol Biochem Behav, 2002, 73(4):883-892. [5] Anderson G, Christrup L L, Sjogren P, et al. Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment[J]. J Pain Symptom Manag, 2002, 23(2):161-164. [6] Coffman B L, Kearney W R, Green M D, et al. Analysis of opioid binding to UDP-glucuronosyltransferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy[J]. Mol Pharmacol, 2001, 59(6):1464-1469. [7] NCCN. clinical practice guidelines in Oncology:Adult Cancer Pain(Version2.2013)[EB/OL].(2013-05-29)[2016-12-23]. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [8] Klepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: A European genetic association study of 2294 cancer pain patients[J]. PAIN, 2011, 152(5):1139-1145. [9] Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study[J]. J Support Oncol. 2011, 9(6):224-231. [10] U.S.Department of health and human services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events [EB/OL]. (2009-05-28)[2016-12-23]. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. [11] 易娟, 谢海棠, 周宏灏. UGT1A9 C2152T和UGT2B7 G211T突变在中国汉族人群中的分布[J]. 中国临床药理学与治疗学, 2007, 12(4):460-464. [12] 许景峰, 赵刚涛, 许茜, 等. 焦磷酸测序技术检测UGT1A3 和UGT2B7在中国汉族人群中的基因多态性[J]. 中南药学, 2011, 9(10):728-733. [13] Tian J N, Ho I K, Tsou H H, et al. UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients[J]. Pharmacogenomics, 2012, 13(8): 879-888. [14] Pasternak G W. The pharmacology of mu analgesics: from patients to genes[J]. Nuroscientist, 2001, 7(3):220-231. [15] De Gregori S, De Gregori M, Ranzani G N, et al. Morphine matebolism, transport and brain disposition[J]. Metab Brain Dis, 2012, 27(1):1-5. [16] Osborne R, Joel S, Trew D, et al. The analgesic activity of morphine -6-glucuronide[J]. Lancet, 1988, 1(8589):828. [17] Joanne D, Joy R, Sophy G, et al. Constipation in cancer patients on morphine[J]. Support Care Cancer, 2008, 16(5):453-459. [18] Cepeda M S, Farrar J T, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race[J]. Clin Pharmacol Ther, 2003, 74(2):102-112. [19] Raffaeli W, Marconi G, Fanelli G, et al. Opioid-related side- effects after intrathecal morphine: A prospective, randomized, double-blind dose-response study[J]. Eur J Anaesthesiol, 2006, 23(7):605-610. [20] Holer P. Treatment of opioid-induced gut dysfunction[J]. Expert Opin investig Drugs, 2007, 16(2):181-194. [21] 刘欣煜,薛钧,朱婷,等. 硫酸吗啡缓释片、盐酸羟考酮缓释片与芬太尼透皮贴剂治疗癌痛引起便秘的风险比较[J]. 中国药房, 2015, 26(3):316-318. |